Results 101 to 110 of about 212,106 (307)

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

Methods to detect minimal residual disease

open access: yesHemaSphere, 2018
Torsten Haferlach
doaj   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

open access: yesMolecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath   +13 more
wiley   +1 more source

Modern possibilities for diagnosing and tumor clone monitoring, determined by multicolor flow cytometry, in Waldenstrom’s macroglobulinemia

open access: yesОнкогематология
Waldenstrom’s macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma that combines lymphoplasmacytic lymphoma substrate in the bone marrow and monoclonal immunoglobulin M secretion in the blood.
A. B. Loginova   +6 more
doaj   +1 more source

Targeting Minimal Residual Disease

open access: yesAnnual Review of Cancer Biology
Minimal residual disease (MRD) represents a significant challenge in the treatment of various cancers, acting as a precursor to relapse and therapeutic resistance. This review discusses the clinical background of MRD, exploring its role as a critical determinant in patient outcomes.
Yu-Ting Chou   +2 more
openaire   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

open access: yesMolecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak   +8 more
wiley   +1 more source

Prognostic Role of Minimal Residual Disease in Mature B-Cell Acute Lymphoblastic Leukemia of Childhood

open access: hybrid, 2007
Lara Mussolin   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy